(Q39118405)

9 September 2017

1 reference

23 October 2022

Antiviral Treatments (English)

1 reference

respiratory tract infection

9 September 2017

main subject

1 reference

23 October 2022

Michael G Ison

1

1 reference

9 September 2017

publication date

13 December 2016

1 reference

Clinics in Chest Medicine

9 September 2017

1 March 2017

1 reference

23 October 2022

2 references

9 September 2017

23 October 2022

38

1 reference

9 September 2017

issue

1

1 reference

9 September 2017

page(s)

139-153

1 reference

A clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adults

9 September 2017

cites work

1 reference

12 December 2020

Efficacy of Oseltamivir-Zanamivir Combination Compared to Each Monotherapy for Seasonal Influenza: A Randomized Placebo-Controlled Trial

1 reference

12 December 2020

DAS181 treatment of severe parainfluenza type 3 pneumonia in a lung transplant recipient

1 reference

12 December 2020

Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients

1 reference

12 December 2020

Antiviral combinations for severe influenza.

1 reference

12 December 2020

Amantadine and rimantadine for influenza A in children and the elderly

1 reference

12 December 2020

Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial

1 reference

12 December 2020

Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study

1 reference

12 December 2020

Pharmacokinetics of oseltamivir in breast milk and maternal plasma

1 reference

12 December 2020

Clinical experience with intravenous zanamivir under an emergency investigational new drug program in the United States

1 reference

12 December 2020

Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro

1 reference

12 December 2020

Laninamivir and its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza

1 reference

12 December 2020

Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein

1 reference

12 December 2020

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.

1 reference

12 December 2020

Effect of a single inhalation of laninamivir octanoate in children with influenza

1 reference

12 December 2020

Zanamivir for the treatment of influenza A and B infection in high-risk patients: a pooled analysis of randomized controlled trials

1 reference

12 December 2020

Oseltamivir: a review of its use in influenza

1 reference

12 December 2020

Management of RSV infections in adult recipients of hematopoietic stem cell transplantation

1 reference

12 December 2020

Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus

1 reference

12 December 2020

Effect of double dose oseltamivir on clinical and virological outcomes in children and adults admitted to hospital with severe influenza: double blind randomised controlled trial

1 reference

12 December 2020

Diagnosis, management and outcomes of adults hospitalized with influenza

1 reference

12 December 2020

Long-acting neuraminidase inhibitor laninamivir octanoate (CS-8958) versus oseltamivir as treatment for children with influenza virus infection

1 reference

12 December 2020

Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial

1 reference

12 December 2020

Molecular basis of resistance of influenza A viruses to amantadine.

1 reference

12 December 2020

Intravenous peramivir for treatment of influenza A and B virus infection in high-risk patients

1 reference

12 December 2020

An open-label crossover study to evaluate potential pharmacokinetic interactions between oral oseltamivir and intravenous zanamivir in healthy Thai adults

1 reference

12 December 2020

Neuraminidase inhibitors for influenza

1 reference

12 December 2020

Sialidase fusion protein as a novel broad-spectrum inhibitor of influenza virus infection.

1 reference

12 December 2020

Combination therapy with amantadine, oseltamivir and ribavirin for influenza A infection: safety and pharmacokinetics

1 reference

12 December 2020

DAS181 treatment of hematopoietic stem cell transplant patients with parainfluenza virus lung disease requiring mechanical ventilation

1 reference

12 December 2020

Oral oseltamivir treatment of influenza in children.

1 reference

12 December 2020

Efficacy and safety of oral oseltamivir for influenza prophylaxis in transplant recipients

1 reference

12 December 2020

Successful Treatment of Parainfluenza Virus Respiratory Tract Infection With DAS181 in 4 Immunocompromised Children

1 reference

12 December 2020

Clinical pharmacokinetics of the prodrug oseltamivir and its active metabolite Ro 64-0802.

1 reference

12 December 2020

Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis

1 reference

12 December 2020

Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09.

1 reference

12 December 2020

Peramivir clearance in continuous renal replacement therapy

1 reference

12 December 2020

The molecular basis of the specific anti-influenza action of amantadine

1 reference

12 December 2020

CMV in critically ill patients: pathogen or bystander?

1 reference

12 December 2020

Oseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza

1 reference

12 December 2020

ALN-RSV01 for prevention of bronchiolitis obliterans syndrome after respiratory syncytial virus infection in lung transplant recipients

1 reference

12 December 2020

Efficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic H1N1 influenza A virus infection

1 reference

12 December 2020

Phase III randomized, double-blind study comparing single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection

1 reference

12 December 2020

Comparison of central nervous system adverse effects of amantadine and rimantadine used as sequential prophylaxis of influenza A in elderly nursing home patients

1 reference

12 December 2020

Cytomegalovirus pneumonia in hematopoietic stem cell recipients.

1 reference

12 December 2020

Long‐Acting Neuraminidase Inhibitor Laninamivir Octanoate versus Oseltamivir for Treatment of Influenza: A Double‐Blind, Randomized, Noninferiority Clinical Trial

1 reference

12 December 2020

A multicenter evaluation of pandemic influenza A/H1N1 in hematopoietic stem cell transplant recipients.

1 reference

12 December 2020

Meeting report: 4th ISIRV antiviral group conference: Novel antiviral therapies for influenza and other respiratory viruses

1 reference

12 December 2020

Safety and efficacy of nebulized zanamivir in hospitalized patients with serious influenza

1 reference

12 December 2020

Emerging Infections: Adenovirus Infections in Transplant Recipients

1 reference

12 December 2020

Effects of oseltamivir on influenza-related complications in children with chronic medical conditions.

1 reference

12 December 2020

Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection

1 reference

12 December 2020

Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebo-controlled, phase 2b/3 trial

1 reference

12 December 2020

Oseltamivir, an influenza neuraminidase inhibitor drug, does not affect the steady-state pharmacokinetic characteristics of cyclosporine, mycophenolate, or tacrolimus in adult renal transplant patients.

1 reference

12 December 2020

Drugs in development for influenza

1 reference

12 December 2020

Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level

1 reference

12 December 2020

A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus

1 reference

12 December 2020

Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.

1 reference

12 December 2020

Mode of action of ribavirin: effect of nucleotide pool alterations on influenza virus ribonucleoprotein synthesis

1 reference

12 December 2020

Newer influenza antivirals, biotherapeutics and combinations

1 reference

12 December 2020

Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation

1 reference

12 December 2020

Zanamivir: a review of its use in influenza

1 reference

12 December 2020

Pharmacokinetics of zanamivir following intravenous administration to subjects with and without renal impairment

1 reference

12 December 2020

Influenza virus M2 protein has ion channel activity

1 reference

12 December 2020

Effect of ribavirin triphosphate on primer generation and elongation during influenza virus transcription in vitro

1 reference

12 December 2020

Influenza treatment and prophylaxis with neuraminidase inhibitors: a review

1 reference

12 December 2020

Oral ribavirin therapy for respiratory syncytial virus infections in moderately to severely immunocompromised patients

1 reference

12 December 2020

Pharmacokinetics of oseltamivir according to trimester of pregnancy

1 reference

12 December 2020

A prospective intervention study on higher-dose oseltamivir treatment in adults hospitalized with influenza a and B infections.

1 reference

12 December 2020

Neuropsychiatric adverse effects of oseltamivir in the FDA Adverse Event Reporting System, 1999-2012.

1 reference

12 December 2020

Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus

1 reference

12 December 2020

Virus-induced acute respiratory distress syndrome: epidemiology, management and outcome

1 reference

12 December 2020

Influenza virus neuraminidase: structure, antibodies, and inhibitors

1 reference

12 December 2020

Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies

1 reference

12 December 2020

Respiratory viral infections in transplant recipients

1 reference

12 December 2020

Intravenous peramivir for treatment of influenza in hospitalized patients.

1 reference

12 December 2020

Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers

1 reference

12 December 2020

The posology of oseltamivir in infants with influenza infection using a population pharmacokinetic approach.

1 reference

12 December 2020

Clinical pharmacokinetics of amantadine hydrochloride.

1 reference

12 December 2020

Overview of the 3rd isirv-Antiviral Group Conference--advances in clinical management

1 reference

12 December 2020

Comparison of the clinical effectiveness of zanamivir and laninamivir octanoate for children with influenza A(H3N2) and B in the 2011-2012 season

1 reference

12 December 2020

Comparative single-dose pharmacokinetics of amantadine hydrochloride and rimantadine hydrochloride in young and elderly adults

1 reference

12 December 2020

Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture

1 reference

12 December 2020

Absence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humans

1 reference

12 December 2020

Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP).

1 reference

12 December 2020

Safety and pharmacokinetics of intravenous zanamivir treatment in hospitalized adults with influenza: an open-label, multicenter, single-arm, phase II study

1 reference

12 December 2020

Nitazoxanide: a first-in-class broad-spectrum antiviral agent

1 reference

12 December 2020

Oral GS-5806 activity in a respiratory syncytial virus challenge study.

1 reference

12 December 2020

GS-5806 inhibits pre- to postfusion conformational changes of the respiratory syncytial virus fusion protein

1 reference

12 December 2020

Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data.

1 reference

12 December 2020

Brincidofovir (CMX001) inhibits BK polyomavirus replication in primary human urothelial cells

1 reference

12 December 2020

The Role of Clinical Pharmacology in Supporting the Emergency Use Authorization of an Unapproved Anti-Influenza Drug, Peramivir

1 reference

12 December 2020

Comparison of elderly people's technique in using two dry powder inhalers to deliver zanamivir: randomised controlled trial

1 reference

12 December 2020

Pharmacokinetics of oseltamivir among pregnant and nonpregnant women

1 reference

12 December 2020

Hospitalizing influenza in adults

1 reference

12 December 2020

A phase II study of DAS181, a novel host directed antiviral for the treatment of influenza infection

1 reference

12 December 2020

Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial

1 reference

12 December 2020

Pharmacokinetics of ribavirin and urinary excretion of the major metabolite 1,2,4-triazole-3-carboxamide in normal volunteers

1 reference

12 December 2020

Adjuvant treatment with a mammalian target of rapamycin inhibitor, sirolimus, and steroids improves outcomes in patients with severe H1N1 pneumonia and acute respiratory failure.

1 reference

12 December 2020

Adenovirus in solid organ transplant recipients

1 reference

12 December 2020

Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.

1 reference

12 December 2020

An adaptive randomized trial of an intermittent dosing schedule of aerosolized ribavirin in patients with cancer and respiratory syncytial virus infection

1 reference

12 December 2020

Editorial commentary. "Late" treatment with neuraminidase inhibitors for severely ill patients with influenza: better late than never?

1 reference

12 December 2020

DAS181, a novel sialidase fusion protein, protects mice from lethal avian influenza H5N1 virus infection.

1 reference

12 December 2020

Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial

1 reference

12 December 2020

Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients

1 reference

12 December 2020

Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations.

1 reference

12 December 2020

Oseltamivir dosing for influenza infection in premature neonates

1 reference

12 December 2020

Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study

1 reference

12 December 2020

A randomized double-blind controlled study of laninamivir compared with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases

1 reference

12 December 2020

Post-marketing assessment of neuropsychiatric adverse events in influenza patients treated with oseltamivir: an updated review

1 reference

12 December 2020

DAS181 for Treatment of Parainfluenza Virus Infections in Hematopoietic Stem Cell Transplant Recipients at a Single Center

1 reference

12 December 2020

Discovery of an oral respiratory syncytial virus (RSV) fusion inhibitor (GS-5806) and clinical proof of concept in a human RSV challenge study

1 reference

12 December 2020

Pharmacokinetic properties of anti-influenza neuraminidase inhibitors

1 reference

12 December 2020

RNA Interference Therapy in Lung Transplant Patients Infected with Respiratory Syncytial Virus

1 reference

12 December 2020

10.1016/J.CCM.2016.11.008

Identifiers

DOI

1 reference

9 September 2017

0 references

1 reference